{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:28:12Z","timestamp":1792081692652,"version":"4.4.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ejpn.2025.03.016","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T23:05:41Z","timestamp":1744758341000},"page":"46-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Treatment of leukodystrophies: Advances and challenges"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1721-0728","authenticated-orcid":false,"given":"Nicole I.","family":"Wolf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8912-0954","authenticated-orcid":false,"given":"Marjo S.","family":"van der Knaap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5346-8497","authenticated-orcid":false,"given":"Marc","family":"Engelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpn.2025.03.016_bib1","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1474-4422(19)30143-7","article-title":"Diagnosis, prognosis, and treatment of leukodystrophies","volume":"18","author":"Knaap van der","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejpn.2025.03.016_bib2","first-page":"1","article-title":"Childhood white matter disorders: much more than just diseases of myelin","author":"Bugiani","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejpn.2025.03.016_bib3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/s-0036-1588020","article-title":"Update on leukodystrophies: a historical perspective and adapted definition","volume":"47","author":"Kevelam","year":"2016","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.ejpn.2025.03.016_bib4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ejpn.2025.03.016_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00443","article-title":"Gene therapy for the leukodystrophies: from preclinical animal studies to clinical trials","volume":"21","author":"Metovic","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejpn.2025.03.016_bib6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/B978-0-323-99209-1.00017-X","article-title":"Chapter 20 Hematopoietic stem cell transplantation in leukodystrophies","volume":"204","author":"Sevin","year":"2024","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.ejpn.2025.03.016_bib7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/acn3.50975","article-title":"Metachromatic leukodystrophy and transplantation: remyelination, no cross\u2010correction","volume":"7","author":"Wolf","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ejpn.2025.03.016_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13773","article-title":"Pubertal outcomes of children transplanted with allogeneic stem cells after myeloablative total body irradiation or busulfan: influence of age and sex is confirmed, while a role of chronic graft\u2010versus\u2010host disease in delayed puberty onset is revealed","volume":"24","author":"Weinhard","year":"2020","journal-title":"Pediatr. Transplant."},{"key":"10.1016\/j.ejpn.2025.03.016_bib9","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bbmt.2011.09.013","volume":"17","author":"Nieder","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ejpn.2025.03.016_bib10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/B978-0-323-90242-7.00018-3","article-title":"Chapter 17 Hematopoietic stem cell therapy and ex vivo gene therapy for X-linked adrenoleukodystrophy","volume":"202","author":"Eichler","year":"2024","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.ejpn.2025.03.016_bib11","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/acn3.526","article-title":"Post\u2010transplant adaptive function in childhood cerebral adrenoleukodystrophy","volume":"5","author":"Pierpont","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ejpn.2025.03.016_bib12","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/brain\/awx016","article-title":"Long-term outcomes of allogeneic haematopoietic stem cell transplantation for adult cerebral X-linked adrenoleukodystrophy","volume":"140","author":"K\u00fchl","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.ejpn.2025.03.016_bib13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10545-014-9797-1","article-title":"Hematopoietic cell transplantation does not prevent myelopathy in X\u2010linked adrenoleukodystrophy: a retrospective study","volume":"38","author":"Geel","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ejpn.2025.03.016_bib14","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/jamaneurol.2013.629","article-title":"Improvement of white matter changes on neuroimaging modalities after stem cell transplant in metachromatic leukodystrophy","volume":"70","author":"Egmond","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejpn.2025.03.016_bib15","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood-2016-03-708479","article-title":"Efficacy of hematopoietic cell transplantation in metachromatic leukodystrophy: the Dutch experience","volume":"127","author":"Rappard","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejpn.2025.03.016_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.51796","article-title":"Neurodegenerative disease after hematopoietic stem cell transplantation in metachromatic leukodystrophy","author":"Al\u2010Saady","year":"2023","journal-title":"Ann. Clin. Transl. Neur."},{"key":"10.1016\/j.ejpn.2025.03.016_bib17","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa042604","article-title":"Transplantation of umbilical-cord blood in babies with infantile krabbe's disease","volume":"352","author":"Escolar","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpn.2025.03.016_bib18","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/GIM.0b013e3181a16e04","article-title":"The long-term outcomes of presymptomatic infants transplanted for Krabbe disease: report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York","volume":"11","author":"Duffner","year":"2009","journal-title":"Genet. Med. : Off. J. Ame. Coll. Med. Genet."},{"key":"10.1016\/j.ejpn.2025.03.016_bib19","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.3390\/pharmaceutics14122778","article-title":"Hematopoietic stem cell transplantation in CSF1R-related leukoencephalopathy: retrospective study on predictors of outcomes","volume":"14","author":"Dulski","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpn.2025.03.016_bib20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/brain\/awz390","article-title":"Allogeneic HSCT for adult-onset leukoencephalopathy with spheroids and pigmented glia","volume":"143","author":"Gelfand","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.ejpn.2025.03.016_bib21","doi-asserted-by":"crossref","first-page":"e1451","DOI":"10.1542\/peds.2013-3604","article-title":"Umbilical cord blood transplantation to treat pelizaeus-merzbacher disease in 2 young boys","volume":"134","author":"Wishnew","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.ejpn.2025.03.016_bib22","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejpn.2025.03.016_bib23","doi-asserted-by":"crossref","unstructured":"Sevin C, Verot L, Benraiss A, et al. Partial Cure of Established Disease in an Animal Model of Metachromatic Leukodystrophy after Intracerebral Adeno-Associated Virus-Mediated Gene Transfer. ; vol. 14. DOI:10.1038\/sj.gt.3302883.","DOI":"10.1038\/sj.gt.3302883"},{"key":"10.1016\/j.ejpn.2025.03.016_bib24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/humc.2014.139","article-title":"Intracerebral gene therapy using AAVrh.10-hARSA recombinant vector to treat patients with early-onset forms of metachromatic leukodystrophy: preclinical feasibility and safety assessments in nonhuman primates","volume":"26","author":"Zerah","year":"2015","journal-title":"Human Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ejpn.2025.03.016_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2017.12.352","article-title":"Intracerebral gene therapy in children with metachromatic leukodystrophy: results of a phase I\/II trial","volume":"123","author":"Sevin","year":"2018","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.ejpn.2025.03.016_bib26","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJMoa2400442","article-title":"Lentiviral gene therapy for cerebral adrenoleukodystrophy","volume":"391","author":"Eichler","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpn.2025.03.016_bib27","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpn.2025.03.016_bib28","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa2405541","article-title":"Hematologic cancer after gene therapy for cerebral adrenoleukodystrophy","volume":"391","author":"Duncan","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpn.2025.03.016_bib29","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/mt.2016.68","article-title":"rAAV gene therapy in a canavan's disease mouse model reveals immune impairments and an extended pathology beyond the central nervous system","volume":"24","author":"Ahmed","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejpn.2025.03.016_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001522","article-title":"Identification of hematopoietic stem cell\u2013specific miRNAs enables gene therapy of globoid cell leukodystrophy","volume":"2","author":"Gentner","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejpn.2025.03.016_bib31","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.ymthe.2021.01.026","article-title":"Waning efficacy in a long-term AAV-mediated gene therapy study in the murine model of Krabbe disease","volume":"29","author":"Heller","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejpn.2025.03.016_bib32","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41586-020-2494-3","article-title":"Suppression of proteolipid protein rescues Pelizaeus\u2013Merzbacher disease","volume":"585","author":"Elitt","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejpn.2025.03.016_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg4711","article-title":"Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment","volume":"13","author":"Hagemann","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejpn.2025.03.016_bib34","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpn.2025.03.016_bib35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.omtm.2022.02.006","article-title":"In vivo targeting of a variant causing vanishing white matter using CRISPR\/Cas9","volume":"25","author":"Hillen","year":"2022","journal-title":"Mol. Ther. - Meth. Clin. Dev."},{"key":"10.1016\/j.ejpn.2025.03.016_bib36","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/acn3.50826","article-title":"Vanishing white matter: deregulated integrated stress response as therapy target","volume":"6","author":"Abbink","year":"2019","journal-title":"Ann. Clin. Transl. Neur."},{"key":"10.1016\/j.ejpn.2025.03.016_bib37","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/acn3.51611","article-title":"Guanabenz ameliorates disease in vanishing white matter mice in contrast to sephin1","volume":"9","author":"Witkamp","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ejpn.2025.03.016_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cei.12115","article-title":"Therapies in aicardi\u2013gouti\u00e8res syndrome","volume":"175","author":"Crow","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ejpn.2025.03.016_bib39","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1056\/NEJMc2001362","article-title":"Janus kinase inhibition in the aicardi\u2013gouti\u00e8res syndrome","volume":"383","author":"Vanderver","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpn.2025.03.016_bib40","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1056\/NEJMc1810983","article-title":"Reverse-transcriptase inhibitors in the aicardi\u2013gouti\u00e8res syndrome","volume":"379","author":"Rice","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpn.2025.03.016_bib41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1474-4422(22)00495-1","article-title":"Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2\u20133 trial","volume":"22","author":"K\u00f6hler","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejpn.2025.03.016_bib42","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1093\/brain\/awae169","article-title":"Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy","volume":"147","author":"Golse","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.ejpn.2025.03.016_bib43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymgme.2017.08.006","article-title":"Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies","volume":"122","author":"Adang","year":"2017","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.ejpn.2025.03.016_bib44","article-title":"Intrathecal baclofen in metachromatic leukodystrophy","author":"Veldt","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ejpn.2025.03.016_bib45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.parkreldis.2021.02.018","article-title":"Adult onset POLR3A leukodystrophy presenting with parkinsonism treated with pallidal deep brain stimulation","volume":"85","author":"Kyle","year":"2021","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.ejpn.2025.03.016_bib46","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ymgme.2015.01.014","article-title":"Disease specific therapies in leukodystrophies and leukoencephalopathies","volume":"114","author":"Helman","year":"2015","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.ejpn.2025.03.016_bib47","article-title":"The natural history of adrenal insufficiency in X-linked adrenoleukodystrophy: an international collaboration","author":"Huffnagel","year":"2018","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.ejpn.2025.03.016_bib48","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/B978-0-12-819973-2.00018-6","article-title":"Chapter 18 Endocrine dysfunction in adrenoleukodystrophy","volume":"182","author":"Engelen","year":"2021","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.ejpn.2025.03.016_bib49","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1093\/brain\/awp171","article-title":"Natural history of adult-onset eIF2B-related disorders: a multi-centric survey of 16 cases","volume":"132","author":"Labauge","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.ejpn.2025.03.016_bib50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1212\/WNL.0000000000002811","article-title":"Gallbladder and the risk of polyps and carcinoma in metachromatic leukodystrophy","volume":"87","author":"Rappard","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2025.03.016_bib51","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1212\/WNL.0000000000001002","article-title":"Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations","volume":"83","author":"Wolf","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2025.03.016_bib52","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/jimd.12571","article-title":"Sex\u2010specific newborn screening for X\u2010linked adrenoleukodystrophy","volume":"46","author":"Albersen","year":"2023","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ejpn.2025.03.016_bib53","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJMc2407165","article-title":"Newborn screening and presymptomatic treatment of metachromatic leukodystrophy","volume":"391","author":"Laugwitz","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpn.2025.03.016_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/ajmg.a.63995","article-title":"Insights from Minnesota on newborn screening for adrenoleukodystrophy: a 5\u2010year update","author":"Rayannavar","year":"2025","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.ejpn.2025.03.016_bib55","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2024-069152","article-title":"Evidence and recommendation for infantile Krabbe disease newborn screening","author":"Ream","year":"2025","journal-title":"Pediatrics"},{"key":"10.1016\/j.ejpn.2025.03.016_bib56","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209743","article-title":"Framework for multistakeholder patient registries in the field of rare diseases","volume":"103","author":"Schoenmakers","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2025.03.016_bib57","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/jimd.12753","article-title":"International validation of meaningfulness of postural sway and gait to assess myeloneuropathy in adults with adrenoleukodystrophy","volume":"47","author":"Yska","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ejpn.2025.03.016_bib58","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12883-023-03354-9","article-title":"Core protocol development for phase 2\/3 clinical trials in the leukodystrophy vanishing white matter: a consensus statement by the VWM consortium and patient advocates","volume":"23","author":"Schoenmakers","year":"2023","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ejpn.2025.03.016_bib59","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13063-024-08100-1","article-title":"A methodological review of randomised n-of-1 trials","volume":"25","author":"Hawksworth","year":"2024","journal-title":"Trials"},{"key":"10.1016\/j.ejpn.2025.03.016_bib60","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pediatrneurol.2021.09.012","article-title":"Reliability of the telemedicine application of the gross motor function measure-88 in patients with leukodystrophy","volume":"125","author":"Gavazzi","year":"2021","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ejpn.2025.03.016_bib61","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejpn.2024.03.003","article-title":"Newborn screening in metachromatic leukodystrophy \u2013 European consensus-based recommendations on clinical management","volume":"49","author":"Laugwitz","year":"2024","journal-title":"Eur. J. Paediatr. Neurol."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109037982500056X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109037982500056X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T15:23:06Z","timestamp":1748877786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109037982500056X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":61,"alternative-id":["S109037982500056X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2025.03.016","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of leukodystrophies: Advances and challenges","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2025.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}